Literature DB >> 30519939

Phenotypic Screening Using Mouse and Human Stem Cell-Based Models of Neuroinflammation and Gene Expression Analysis to Study Drug Responses.

Masin Abo-Rady1, Jessica Bellmann1, Michael Glatza2, Lara Marrone1, Lydia Reinhardt1,2, Santiago Tena1, Jared Sterneckert3.   

Abstract

High-throughput phenotypic screening enables the identification of new therapeutic targets even when the molecular mechanism underlying the disease is unknown. In the case of neurodegenerative disease, there is a dire need to identify new targets that can ameliorate, halt, or reverse degeneration. Stem cell-based disease models are particularly powerful tools for phenotypic screening because they use the same cell type affected in patients. Here, we describe the expansion of mouse stem cells and human induced pluripotent stem cells as well as the differentiation of these cells into neural lineages that, when exposed to neuroinflammatory stress, can be used for compound screening followed by hit identification, validation, and target deconvolution.

Entities:  

Keywords:  Disease modelling; Neurodegeneration; Neuroinflammation; Neuronal differentiation; Phenotypic screening; Pluripotent stem cells; Target deconvolution

Mesh:

Substances:

Year:  2019        PMID: 30519939     DOI: 10.1007/978-1-4939-8891-4_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Physiologic Targets and Modes of Action for CBL0137, a Lead for Human African Trypanosomiasis Drug Development.

Authors:  Carlos E Sanz-Rodriguez; Benjamin Hoffman; Paul J Guyett; Andrei Purmal; Baljinder Singh; Michael Pollastri; Kojo Mensa-Wilmot
Journal:  Mol Pharmacol       Date:  2022-05-23       Impact factor: 4.054

2.  Using High-Content Screening to Generate Single-Cell Gene-Corrected Patient-Derived iPS Clones Reveals Excess Alpha-Synuclein with Familial Parkinson's Disease Point Mutation A30P.

Authors:  Peter Barbuti; Paul Antony; Bruno Santos; François Massart; Gérald Cruciani; Claire Dording; Jonathan Arias; Jens Schwamborn; Rejko Krüger
Journal:  Cells       Date:  2020-09-10       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.